GRAY SUSANNAH — SEC insider filings
SEC reporting owner CIK 1833453. 30 insider filings on record with FilingPulse; latest filed 2026-09-24.
Transaction summary — filings shown
Covers all 30 filings on record, filed 2020-11-23 to 2026-09-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 20,000 shares, $540,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 45.
- Largest priced transaction: purchase of 20,000 shares @ $27.00 ($540,000) in MARAVAI LIFESCIENCES HOLDINGS, INC., filed 2020-11-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Director | 7 | 1 leg · 20,000 sh · $540,000 | — | 6 |
| Theravance Biopharma, Inc. (TBPH) | Director | 6 | — | — | 19 |
| Morphic Holding, Inc. (MORF) | Director | 8 | — | — | 11 |
| 4D Molecular Therapeutics, Inc. (FDMT) | Director | 6 | — | — | 6 |
| Apria, Inc. (APR) | Director | 2 | — | — | 2 |
| ANAPTYSBIO, INC (ANAB) | Director | 1 | — | — | 1 |
Insider filings — GRAY SUSANNAH
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-24 | 4 | Theravance Biopharma, Inc. (TBPH) | Disposition to issuer (D): 42,137 · Disposition to issuer (D): 6,009 · Disposition to issuer (D): 32,666 (derivative) · Disposition to issuer (D): 22,044 (derivative) · Disposition to issuer (D): 23,576 (derivative) · Disposition to issuer (D): 24,258 (derivative) · +1 more | EDGAR |
| 2026-06-18 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 46,293 @ $0 | EDGAR |
| 2026-04-29 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 11,250 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 89,139 @ $2.16 | EDGAR |
| 2025-05-21 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,649 @ $0 · Grant/award (A): 24,258 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Morphic Holding, Inc. (MORF) | Disposition to issuer (D): 18,111 (derivative) · Disposition to issuer (D): 17,550 (derivative) · Disposition to issuer (D): 12,535 (derivative) · Disposition to issuer (D): 23,168 (derivative) | EDGAR |
| 2024-06-05 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 23,168 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 20,645 @ $10.78 | EDGAR |
| 2024-05-23 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,537 @ $0 · Grant/award (A): 23,576 (derivative) @ $0 | EDGAR |
| 2023-07-19 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 24,000 @ $0 | EDGAR |
| 2023-06-02 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 12,535 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | 4D Molecular Therapeutics, Inc. (FMDT) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2023-05-04 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 9,132 @ $0 · Grant/award (A): 22,044 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,131 @ $0 · Grant/award (A): 1,688 @ $0 · Grant/award (A): 28,000 (derivative) @ $0 · Grant/award (A): 4,666 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 17,550 (derivative) @ $0 | EDGAR |
| 2022-05-25 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2022-04-29 | 4/A | Morphic Holding, Inc. (MORF) | Grant/award (A): 0 (derivative) @ $0 | EDGAR |
| 2022-04-29 | 4/A | Morphic Holding, Inc. (MORF) | Grant/award (A): 18,111 (derivative) @ $0 | EDGAR |
| 2022-03-29 | 4 | Apria, Inc. (APR) | Disposition to issuer (D): 5,059 (derivative) @ $37.50 | EDGAR |
| 2021-11-23 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 4,271 @ $0 | EDGAR |
| 2021-06-17 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | Apria, Inc. (APR) | Grant/award (A): 5,059 (derivative) @ $0 | EDGAR |
| 2021-05-19 | 4 | 4D Molecular Therapeutics Inc. (FDMT) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2021-04-29 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2020-11-25 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Purchase (P): 20,000 @ $27 | EDGAR |
| 2020-11-23 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 11,852 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1833453 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs